Content
Week In Review: CMBG Out-Licenses Two CAR-T Candidates To Janssen For $245 Million Upfront
Article By:
ChinaBio® Today
Read
Saturday, July 1, 2023 2:58 PM EDT
Cellular Biomedicine Group out-licensed global rights to its two lead CAR-T candidates to Janssen Biotech for $245 million upfront, plus milestones. Also, Shanghai Laekna Therapeutics completed an IPO on the Hong Kong Exchange, raising $100 million.
Back To The 50s – When Military Equipment Ruled!
Article By:
Martin Hutchinson
Read
Monday, June 26, 2023 8:21 AM EDT
Even as a participant in the derivatives market, I found new derivatives wrinkles pretty boring, however lucrative they might be. Equally in software, the latest “social media” app, however irresistible to billions of dozy consumers, leaves me cold.
Bitcoin Futures See Record-High Inflows Amidst Ongoing Spot ETF Wave
Article By:
Invezz
Read
Monday, June 26, 2023 6:50 AM EDT
Bitcoin exchange-traded funds see increased excitement from market participants, with new ETF applications and the latest uptick in fund inflows. ProShare’s futures fund, BITO, recently recorded its highest weekly inflow, totaling around $65 million.
Adapting To The AI Revolution: Don’t Just Hand Over The Tools, Rework The Workflow
Article By:
Shelly Palmer
Read
Sunday, June 25, 2023 2:32 PM EDT
Embracing generative AI is not just about adopting a new tool, it’s about reimagining how we work.
In this article: AIQ
Recession Probabilities Based On Multiple Financial Measures
Article By:
Menzie Chinn
Read
Sunday, June 25, 2023 9:07 AM EDT
Assume no recession in US through February 2023. What do term and credit spreads, financial conditions index, debt-service ratios predict?
S&P 500 Likely To Pull Back To Its Trendline...but That's Okay
Article By:
MoneyShow.com
Read
Sunday, June 25, 2023 7:16 AM EDT
Stocks ended last week higher but ended the day lower on Friday as new concerns caused investors some anxiety. Yes, the Fed skipped on a rate increase, but it made it clear that investors should not expect a halt or a decline in rates anytime soon.
In this article: SPX
The Spectacular Past And Concerning Future Of The 60-40 Portfolio
Article By:
AllAboutAlpha
Read
Sunday, June 25, 2023 6:01 AM EDT
We believe that perhaps no innovation in the history of investing has created more wealth than the 60/40 Portfolio. This portfolio invests its total value in 2 market segments, with 60% of the value invested in stocks and the remaining 40% in bonds.
Comparing Carmaker Revenue Vs. Country GDP
Article By:
Jeff Desjardins
Read
Sunday, June 25, 2023 4:58 AM EDT
As of July 2022, the global car and manufacturing market was worth about $2.9T. What companies are currently dominating this massive industry, and how much revenue do they generate on a yearly basis compared to the economic output of countries?
Macro: Residential Construction
Article By:
Joseph Calhoun
Read
Thursday, June 22, 2023 4:29 AM EDT
Housing starts rebounded nicely in May to 1631 units from a revised lower 1340 units in April. Permits went up sequentially as well, just not as much. Both series are above the historic mean and median levels.
Market Blast – Wednesday, June 21
Article By:
Bob Lang
Read
Wednesday, June 21, 2023 9:02 AM EDT
Futures are mixed this morning as the markets prepare for words from Chair Powell on the Hill. He starts is bi-annual testimony today in front of Congress, tomorrow in front of the Senate. There is often a market response to his words or comments.
Chinese Stock Market Slips As Investors Await PBOC’s Loan Prime Rate Decision
Article By:
The Private Banker
Read
Monday, June 19, 2023 7:44 AM EDT
Shanghai Composite and Shenzhen Component experienced losses, with a 0.54% and 0.29% decrease respectively, as investors awaited the People’s Bank of China’s decision on the loan prime rate.
Huge Growth In China's Aircraft Industry Is Flying Under The Radar
Article By:
Mish Shedlock
Read
Sunday, June 18, 2023 6:25 AM EDT
Let's discuss Lyn Alden's thought provoking Tweets on China's aircraft industry.
Week In Review: Cullgen Signs $1.9 Billion Protein Degrader Deal With Astellas
Article By:
ChinaBio® Today
Read
Saturday, June 17, 2023 3:00 PM EDT
Cullgen will collaborate with Astellas Pharma to discover protein degraders in a deal worth up to $1.9 billion. Meanwhile, Cholesgen formed a collaboration with AstraZeneca to develop new candidates for hypercholesterolemia and metabolic diseases.
Thoughts For Thursday: The Pause That Refreshes?
Article By:
TalkMarkets DailyTalk
Read
Thursday, June 15, 2023 7:02 AM EDT
Yesterday the Fed, as expected did not increase the Fed funds rate. It remains to be seen if this pause will relieve some of the current strain in the credit markets without fueling inflation.